# MicroRNA Profiles in Triple Negative Breast Cancer

> **NCT04771871** · PHASE2 · RECRUITING · sponsor: **University College Hospital, Ibadan** · enrollment: 42 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04771871
- **Lead sponsor:** University College Hospital, Ibadan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-29
- **Primary completion:** 2027-03
- **Final completion:** 2030-08
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04771871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04771871, "MicroRNA Profiles in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04771871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*